Recent progress and clinical importance on pharmacogenetics in cancer therapy
- 1 January 2011
- journal article
- review article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (10) , 1621-1632
Abstract
Recent advances have provided unprecedented opportunities to identify prognostic and predictive markers of efficacy of cancer therapy. Genetic markers can be used to exclude patients who will not benefit from therapy, exclude patients at high risk of severe toxicity and adjust dosing. Genomic approaches for marker discovery now include genome-wide association studies and tumor DNA sequencing. The challenge is now to select markers for which there is enough evidence to transition them to the clinic. The hurdles include the inherent low frequency of many of these markers, the lengthy validation process through trials, as well as legislative and economic hurdles. Attempts to answer questions about certain markers more quickly have led to an increased popularity of trials with enrichment design, especially in light of the dramatic phase I results seen in recent months. Personalized medicine in oncology is a step closer to reality.Keywords
This publication has 108 references indexed in Scilit:
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record TimeCancer Cell, 2010
- Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancerCancer, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphismBritish Journal of Cancer, 2010
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerBritish Journal of Cancer, 2009
- Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndromeCancer, 2007
- Genes, environment and the value of prospective cohort studiesNature Reviews Genetics, 2006
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006
- A physical map of the human genomeNature, 2001